Combination immuno-oncology therapy with pembrolizumab, an anti-PD-1 monoclonal antibody targeting immune evasion, and standard chemotherapy for patients with the squamous and non-squamous subtypes of non-small cell lung cancer

对于非小细胞肺癌的鳞状细胞癌和非鳞状细胞癌亚型患者，采用帕博利珠单抗（一种靶向免疫逃逸的抗PD-1单克隆抗体）联合标准化疗的免疫肿瘤疗法。